Update on Biomarkers for the Stratification of Indeterminate Pulmonary Nodules.
Rafael Paez, Michael N Kammer, Nicole T Tanner...
https://pubmed.ncbi.nlm.nih.gov/37244587/Actively Recruiting
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-06-02
300
Participants Needed
3
Research Sites
52 weeks
Total Duration
Researchers are evaluating a radiomics-based computer-aided diagnosis CAD tool to help doctors manage pulmonary nodules PNs compared to usual care. This pragmatic clinical trial involves adults aged 35 to 89 years who have PNs measuring 8 to 30mm. The goal is to improve the accuracy of malignancy risk assessment for these nodules, which is important to diagnose lung cancer early and avoid unnecessary procedures. The study is sponsored by Abramson Cancer Center at Penn Medicine.
CONDITIONS
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
R
Roger Y. Kim, MD, MSCE
A
Anil Vachani, MD, MSCE
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Abramson Cancer Center at Penn Medicine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Clinician assessment plus Optellum Virtual Nodule Clinic | Usual clinician assessment |
|---|---|---|
| What it is | Management decisions made by a clinician who uses both usual assessment methods and the Optellum Virtual Nodule Clinic, an AI-based, computer-aided diagnostic tool that provides CT-based malignancy risk stratification for indeterminate pulmonary nodules. | Assessment and management decisions made by a pulmonologist or radiologist based on review of CT imaging and established clinical risk models, without use of artificial intelligence tools. |
| Role in the trial | Serves as the investigational approach, with clinicians making management decisions with additional input from the Optellum device. | Serves as the comparator group in the trial, reflecting current standard clinician judgement without AI support. |
| Primary use | Assists clinicians by providing a malignancy risk score for indeterminate pulmonary nodules to inform management decisions, aiming to improve diagnostic accuracy and care pathways. | Diagnosis and risk assessment of newly discovered solid or part-solid indeterminate pulmonary nodules, guiding further work-up or surveillance per clinical judgement. |
| How it is given or performed | The Optellum VNC software analyzes chest CT scans and generates a risk score, which the clinician reviews in addition to their usual workflow before making diagnostic and management decisions. | Management decisions are made by the clinician using their interpretation of CT images along with clinical information and guidelines. No additional software is used. |
| Evidence status | AI-based risk stratification tools—including the Optellum VNC—have shown improved diagnostic accuracy and decision support for indeterminate pulmonary nodules in clinical studies; ongoing research is assessing their impact on management decisions and patient outcomes. | Widely established and evidence-based as the current approach for evaluating indeterminate pulmonary nodules. |
| Important limitations | AI-based risk scores may be inaccurate in some cases, especially if CT quality or nodule characteristics fall outside validated parameters. Not all clinicians may interpret or apply AI outputs consistently. | Accuracy may vary between clinicians; diagnostic uncertainty can lead to delayed or unnecessary procedures. No support from advanced AI-based tools. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Within 60 days of the clinic visit
Participants undergo evaluation of their pulmonary nodules using either usual clinician assessment or clinician assessment combined with a computer-aided diagnosis tool based on CT imaging.
1 baseline visit (in-person)
Duration - 12 months
Participants are monitored for appropriate management of pulmonary nodules and related outcomes over 12 months.
Follow-up visits as scheduled by clinicians
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Rafael Paez, Michael N Kammer, Nicole T Tanner...
https://pubmed.ncbi.nlm.nih.gov/37244587/Roger Y Kim, Jason L Oke, Travis L Dotson...
https://pubmed.ncbi.nlm.nih.gov/37017091/David R Baldwin, Jennifer Gustafson, Lyndsey Pickup...
https://pubmed.ncbi.nlm.nih.gov/32139611/Rafael Paez, Michael N Kammer, Aneri Balar...
https://pubmed.ncbi.nlm.nih.gov/37061539/Roger Y Kim
https://pubmed.ncbi.nlm.nih.gov/38427470/Pierre P Massion, Sanja Antic, Sarim Ather...
https://pubmed.ncbi.nlm.nih.gov/32326730/Roger Y Kim, Jason L Oke, Lyndsey C Pickup...
https://pubmed.ncbi.nlm.nih.gov/35608444/Abramson Cancer Center at Penn Medicine
Lead Sponsor